Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant
Joseph E. Rower; Tia S. Freeman; Cassandra E. Deering-Rice; Kimberly M. MolinaShow moreShow less
1. Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, USA; 2. Center for Human Toxicology, University of Utah College of Pharmacy, Salt Lake City, USA; 3. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, USA; 4. Primary Children’s Medical Center, Intermountain Healthcare, Salt Lake City, USA; 5. Division of Cardiology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, USA; 6. Department of Pediatrics, Dartmouth Hitchcock Medical Center, Lebanon, USAShow moreShow less
Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants
Amy L. Pasternak; William Tackett; Mousumi Banerjee; Simi Paul; Emily Bertucci-Richter; Xiang Zhou; Vaibhav Sahai; Daniel L. HertzShow moreShow less
1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, USA; 2. Department of Pharmacy, University of Michigan Health, Ann Arbor, USA; 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, USA; 4. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USAShow moreShow less
Bridging the pharmacogenomics gap: a survey of healthcare workers in South-Western Nigeria
Ochuko M. Orherhe; Omolabake F. Ayodele; Jeremiah O. Omojuyigbe; Ayodapo O. Jegede; Olumide A. Alade; Kikelomo Oladimeji; Oluwatimilehin S. Ogunde; Promise U. Okereke; Oluwafemi O. Agboola; Moteehat O. Olu-Lawal; Olusanya Aluko; Babatunde A. Adeagbo; Oluseye O. BolajiShow moreShow less
1. Department of Clinical Pharmacy and Pharmacy Administration, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 2. Department of Pharmacology, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria; 3. Department of Nursing, General Hospital, Ifako Ijaiye, Nigeria; 4. Department of Dentistry, Faculty of Dentistry, Obafemi Awolowo University, Ile-Ife, Nigeria; 5. Department of Dentistry, College of Medicine, University College Hospital, Ibadan, Nigeria; 6. Department of Public Health, Ministry of Health, Osogbo, Nigeria; 7. Osun State Hospital Management Board, Osogbo, Nigeria; 8. Department of Pharmacy, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria; 9. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, NigeriaShow moreShow less
The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine
Najmeh Ahangari; Mohammad Doosti; Mojtaba Safi; Narges Hashemi; Shima Imannezhad; Bita Barazandeh; Ehsan Ghayoor Karimiani; Mehran Beiraghi ToosiShow moreShow less
1. Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 2. Rare Pediatric Neurological Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; 3. Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran; 4. 7 Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK, Institute of Neurology, London, UKShow moreShow less
Risk of drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele
Jeong-Hoon Han; Raúl J. Andrade; Einar Stefán Björnsson; James Hendricks Lewis; M. Isabel Lucena; Suyoung Go; Simona Stankeviciute; Guruprasad P. Aithal; Kyuchan Kim; Chong Sik Lee; Carrolee Barlow; Eunhee KimShow moreShow less
1. Kainos Medicine, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea; 2. Department of Medicine and Gastroenterology Service, IBIMA-Plataforma Bionand, Hospital Universitario Virgen de la Victoria, University of Málaga, Málaga, Spain; 3. Centro de Investigación en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain; 4. Department of Internal Medicine, Landspitali University Hospital, University of Iceland, Reykjavík, Iceland; 5. Faculty of Medicine, University of Iceland, Reykjavík, Iceland; 6. Division of Gastroenterology, Department of Medicine, Georgetown University, Washington, USA; 7. Servicio de Farmacología Clínica, IBIMA-Plataforma Bionand, Hospital Universitario Virgen de la Victoria, University of Málaga, Málaga, Spain; 8. Regulatory Consulting, Parexel International, 2520 Meridian Parkway, Durham, USA; 9. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, and the University of Nottingham, Nottingham, UK; 10. Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Republic of KoreaShow moreShow less
Barriers and facilitators to the implementation of pharmacogenomic testing for antidepressants use in primary care: a systematic review using the consolidated framework for implementation research
Muireann Counihan; Deirdre Cushen; Sookyung Kwak; Amy Allen; Donnchadh Fitzsimons Mac Giolla Chuda; Weronika Romanska; Ibrahim Nakchbandi; Rose Reynolds; Chad Bousman; Mark Ledwidge; Joseph Gallagher; Cristín RyanShow moreShow less
1. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland; 2. Department of Medical Genetics, University of Calgary, Calgary, Canada; 3. School of Medicine, University College Dublin, Belfield, IrelandShow moreShow less
FAQ
How long does PHARMACOGENOMICS JOURNAL take to review a manuscript?
As of 2026-11-19, CrushSCI has 15 complete review records for PHARMACOGENOMICS JOURNAL. The fastest paper went from submission to acceptance in 77 days (Effects of CYP3A4, CYP3A5 , and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation, received 2026-05-06, accepted 2026-07-22); the slowest took 791 days. The average is 246.2 days and the median is 212 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
